

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



LSHTM Research Online

Novak, Ryan T; Moisi, Jennifer C; Tall, Haoua; Preziosi, Marie-Pierre; Hadler, Stephen C; Messonnier, Nancy E; Mihigo, Richard; MenAfriNet Consortium; (2019) Country Data for Action: The MenAfriNet Experience in Strengthening Meningitis Surveillance in Africa. *The Journal of infectious diseases*, 220 (Supple). S137-S139. ISSN 0022-1899 DOI: <https://doi.org/10.1093/infdis/jiz347>

Downloaded from: <http://researchonline.lshtm.ac.uk/id/eprint/4655189/>

DOI: <https://doi.org/10.1093/infdis/jiz347>

Usage Guidelines:

Please refer to usage guidelines at <https://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: Copyright the publishers

<https://researchonline.lshtm.ac.uk>

Country Data for Action: The MenAfriNet Experience in Strengthening Meningitis Surveillance in Africa

Ryan T. Novak,^{1,6} Jennifer C. Moisi,^{2,a} Haoua Tall,³ Marie-Pierre Preziosi,⁴ Stephen C. Hadler,^{1,b} Nancy E. Messonnier,¹ and Richard Mihigo,⁵ for the MenAfriNet Consortium^c

¹National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; ²Agence de Médecine Préventive, Paris, France; ³Agence de Médecine Préventive, Ouagadougou, Burkina Faso; ⁴World Health Organization, Geneva, Switzerland; and ⁵World Health Organization Regional Office for Africa, Brazzaville, Republic of the Congo

Keywords. MenAfriNet; meningitis; surveillance; Africa.

Epidemic meningitis has posed a recurrent threat for more than a century for the approximately 430 million people living in the 26 countries in the sub-Saharan region of Africa known as the “meningitis belt.” This population experiences high rates of endemic meningitis, annual seasonal outbreaks, and explosive epidemics occurring every 5–12 years. Hope to eliminate this devastating public health threat came in the form of a novel meningococcal serogroup A conjugate vaccine (MACV [MenAfriVac]) developed by the Meningitis Vaccine Project (MVP; available at: <http://www.meningvax.org>) specifically for use in the meningitis belt and priced at less than \$1.00 per dose [1]. Licensed in 2009, MACV was subsequently prequalified by the World Health Organization (WHO) on the basis of its safety and immunogenicity data but without phase 3 efficacy studies. Starting in 2010, MACV was rolled out across the meningitis belt via mass campaigns to vaccinate all persons 1–29 years of age. By the end of 2018, >300 million people in 22 African countries had been immunized with MACV [2]. The vaccine has been a remarkable public health success, effectively eliminating serogroup A meningitis epidemics in sub-Saharan Africa [3].

Recognizing the need for rigorous postrollout surveillance and research to demonstrate the direct and indirect effectiveness of MACV beyond the conclusion of the MVP [4–6], the Bill and Melinda Gates Foundation awarded a grant in October 2013 to establish the MenAfriNet Consortium (available at: <http://www.menafri.net.org>). MenAfriNet is an international consortium led and implemented by the African Ministries of Health, the Agence de Médecine Préventive, the Centers for Disease Control

and Prevention (CDC), and the WHO, with support and collaboration from other international and nongovernmental organizations. By implementing a surveillance and research platform in 5 African meningitis belt countries (Burkina Faso, Chad, Mali, Niger, and Togo), MenAfriNet aimed to strengthen case-based meningitis surveillance, assess changes in meningitis epidemiology and MACV impact, and inform vaccine policy and development. This supplement aims to summarize the work conducted in the first 5 years of MenAfriNet, including regional and country perspectives on the MenAfriNet strategy of reinforcing case-based surveillance, updates on bacterial meningitis epidemiology and MACV impact, examples of research that leveraged the MenAfriNet platform, and future directions toward defeating epidemic meningitis in the African meningitis belt.

MenAfriNet took an innovative approach to vaccine evaluation by strengthening existing country-level meningitis surveillance systems and laboratory capacity to gather high quality case-level data and leveraged this surveillance platform to answer critical research questions about vaccine effectiveness [7–10]. The MenAfriNet approach has focused on country ownership of activities, planning, and budgeting and has made significant progress toward stronger, sustainable public health surveillance systems in Burkina Faso, Chad, Mali, Niger, and Togo [7, 11–14]. Secondarily, MenAfriNet has had a positive impact on other countries in the region, including Benin, Ghana, Guinea, and Nigeria, through the distribution of MenAfriNet-developed surveillance and laboratory tools and protocols, as well as regional trainings and technical assistance provided by consortium members [10].

A number of articles in this supplement present evidence of MACV’s substantial and ongoing impact on meningococcal serogroup A disease and progress toward elimination of serogroup A epidemics in the meningitis belt [14–16]. To date, MenAfriNet data have directly informed numerous public health actions, including policies for the use of MACV to protect new birth cohorts through introduction into routine immunization programs and catch-up campaigns, the detection and response to epidemics due to new emerging strains of

^aPresent affiliation: Pfizer, Paris, France.

^bRetired.

^cMembers are specified at the end of the text.

Correspondence: R. T. Novak, PhD, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, MS H24-6, Atlanta, GA 30329 (bnk4@cdc.gov).

non-A meningococcal serogroups, and the development and use of new vaccines [17–22].

Now at the conclusion of 5 years of experience with the MenAfriNet platform, this supplement was organized as a forum to share the achievements and lessons learned implementing the MenAfriNet strategy to strengthen national systems of surveillance in Africa. Contents include an overview of project implementation and impact in the 5 MenAfriNet countries, reports on epidemiologic issues from each of the project countries, specific research projects that provide insights into the evolving epidemiology of non-A serogroup meningitis and pneumococcal disease in these countries, and a look toward the future goal of eliminating meningitis in the region. These achievements and lessons, combined with a current examination of regional meningitis epidemiology and ongoing monitoring of the impact of existing vaccine programs, will inform the development of new vaccines and strategies to help realize the dream of an Africa free of epidemic meningitis [18, 23].

Notes

Acknowledgments. The MenAfriNet Supplement Steering Committee (LeAnne Fox, Stephen Hadler, Ryan Novak, Christina Ottis, Caelin Potts, Heidi Soeters, and Xin Wang) thanks the guest editors, whose time and thoughtful input helped shape this supplement. We thank the staff members of all of the organizations whose passion and dedication made the MenAfriNet Consortium possible, including the Ministère de la Santé du Burkina Faso, the Ministère de la Santé et de l'Hygiène Publique du Mali, the Ministère de la Santé Publique du Niger, the Ministère de la Santé Publique du Tchad, the Ministère de la Santé et de la Protection Sociale du Togo, the Agence de Médecine Préventive, the CDC, and the WHO; the MenAfriNet Advisory Board and Steering Committee; other international consortium partners, including the CDC Foundation, Davycas International, EpiCentre, Gavi, Médecins Sans Frontières, Meningitis Research Foundation, and the United Nations Children's Fund; MenAfriCar (available at: <http://www.menafriCar.org>) and the MVP, for the experience gleaned from their success; and Christina Ottis, for her unwavering and most valuable support in planning and coordinating the publication of this supplement.

Disclaimer. The findings and conclusions of this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the World Health Organization.

Financial support. This work was funded by the MenAfriNet consortium (www.menafriNet.org) through a grant from the Bill & Melinda Gates Foundation (OPP1084298).

Potential conflicts of interest. J. C. M. participated in the MenAfriNet Consortium while working at Agence de Médecine Préventive but is now an employee of Pfizer. M. P. reports receiving grants from the Bill and Melinda Gates Foundation and

Gavi during the conduct of the study. All other authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Consortium Members

Members of the MenAfriNet Advisory Board and Steering Committee are as follows: David Stephens, Brian Greenwood, Marie-Pierre Preziosi, Dominique Caugant, Samba Sow, F. Marc Laforce, Tumani Corrah, Richard Mihigo, Jason Mwenda, Jennifer Moisi, Haoua Tall, Brad Gessner, Rana Hajjeh, Ryan Novak, Peter Dull, and Catherine Zilber.

References

1. Aguado MT, Jodar L, Granoff D, Rabinovich R, Ceccarini C, Perkin GW. From epidemic meningitis vaccines for Africa to the meningitis vaccine project. *Clin Infect Dis* **2015**; 61(suppl 5):S391–5.
2. Bwaka A, Bitá A, Lingani C, et al. Status of the rollout of the meningococcal serogroup A conjugate vaccine in African meningitis belt countries in 2018. *J Infect Dis* **2019**; 220(Suppl 4):S140–7.
3. Sambo L, Chan M, Davis S, et al. A vaccine meets its promise: success in controlling epidemic meningitis in sub-Saharan Africa. *Clin Infect Dis* **2015**; 61(suppl 5):S387–8.
4. Novak RT, Kambou JL, Diomandé FV, et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. *Lancet Infect Dis* **2012**; 12:757–64.
5. Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. *Lancet* **2014**; 383:40–7.
6. Kristiansen PA, Diomandé F, Ba AK, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. *Clin Infect Dis* **2013**; 56:354–63.
7. Diallo AO, Kiemtore T, Bicaba BW, et al. Development and implementation of a cloud-based meningitis surveillance and specimen tracking system in Burkina Faso, 2018. *J Infect Dis* **2019**; 220(Suppl 4):S198–205.
8. Mbaeyi SA, Lingani C, Diallo AO, et al. Improving case-based meningitis surveillance in 5 countries in the meningitis belt of sub-Saharan Africa, 2015–2017. *J Infect Dis* **2019**; 220(Suppl 4):S155–64.
9. Feagins AR, Vuong J, Fernandez K, et al. The strengthening of laboratory systems in the meningitis belt to improve meningitis surveillance, 2008–2018: a partners' perspective. *J Infect Dis* **2019**; 220(Suppl 4):S175–81.
10. Patel J, Soeters HM, Diallo AO, et al. MenAfriNet: a network supporting case-based meningitis surveillance and

- vaccine evaluation in the meningitis belt of Africa. *J Infect Dis* **2019**; 220(Suppl 4):S148–54.
11. Paye MF, Gamougame K, Payamps SK, et al. Implementation of case-based surveillance and real-time polymerase chain reaction to monitor bacterial meningitis pathogens in Chad. *J Infect Dis* **2019**; 220(Suppl 4):S182–9.
 12. Mounkoro D, Nikiema CS, Maman I, et al. *Neisseria meningitidis* serogroup W meningitis epidemic in Togo, 2016. *J Infect Dis* **2019**; 220(Suppl 4):S216–24.
 13. Sanogo YO, Guindo I, Diarra S, et al. A new sequence type of *Neisseria meningitidis* serogroup C associated with a meningitis outbreak in Mali. *J Infect Dis* **2019**; 220(Suppl 4):S190–7.
 14. Sidikou F, Potts CC, Zaneidou M, et al. Epidemiology of bacterial meningitis in the nine years since meningococcal serogroup A conjugate vaccine introduction—Niger, 2010–2018. *J Infect Dis* **2019**; 220(Suppl 4):S206–15.
 15. Soeters HM, Diallo AO, Bicaba BW, et al. Bacterial meningitis epidemiology in five countries in the meningitis belt of sub-Saharan Africa, 2015–2017. *J Infect Dis* **2019**; 220(Suppl 4):S165–74.
 16. Fernandez K, Lingani C, Aderinola OM, et al. Meningococcal meningitis outbreaks in the African meningitis belt after meningococcal serogroup A conjugate vaccine introduction, 2011–2017. *J Infect Dis* **2019**; 220(Suppl 4):S225–32.
 17. Cooper LV, Ronveaux O, Fernandez K, et al. Spatio-temporal analysis of serogroup C meningococcal meningitis spread in Niger and Nigeria and implications for epidemic response. *J Infect Dis* **2019**; 220(Suppl 4):S244–52.
 18. Alderson MR, LaForce M, Sobanjo-ter Meulen A, Hwang A, Preziosi M-P, Klugman KP. Eliminating meningococcal epidemics from the African meningitis belt: the case for advanced prevention and control using next-generation meningococcal conjugate vaccines. *J Infect Dis* **2019**; 220(Suppl 4):S274–S278.
 19. Retchless AC, Fox LM, Maiden MCJ, et al. Toward a global genomic epidemiology of meningococcal disease. *J Infect Dis* **2019**; 220(Suppl 4):S266–73.
 20. Soeters HM, Kambire D, Sawadogo G, et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis, Burkina Faso, 2016–2017. *J Infect Dis* **2019**; 220(Suppl 4):S253–62.
 21. Zoma RL, Waldorf JA, Tarbangdo F, et al. Evaluation of the impact of meningococcal serogroup A conjugate vaccine introduction on second year of life vaccination coverage in Burkina Faso. *J Infect Dis* **2019**; 220(Suppl 4):S233–43.
 22. Reese HE, Ronveaux O, Mwenda JM, et al. Invasive meningococcal disease in Africa’s meningitis belt—more than just meningitis? *J Infect Dis* **2019**; 220(Suppl 4):S263–5.
 23. Novak RT, Ronveaux O, Bita AF, et al. Future directions for meningitis surveillance and vaccine evaluation in the meningitis belt of sub-Saharan Africa. *J Infect Dis* **2019**; 220(Suppl 4):S279–85.